Epigenomics' Q1 Revenues Rise, Net Loss Declines

Epigenomics' first-quarter revenues increased 36 percent due primarily to milestone payments received from Abbott and new collaborations.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories